Profile data is unavailable for this security.
About the company
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
- Revenue in USD (TTM)0.00
- Net income in USD-81.19m
- Incorporated2014
- Employees94.00
- LocationKorro Bio IncOne Kendall Square. Building 600-700Suite 6-401CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 468-1999
- Fax+1 (302) 636-5454
- Websitehttps://www.korrobio.com/
Mergers & acquisitions
Acquired company | KRRO:NAQ since announced | Transaction value |
---|---|---|
Korro Bio Inc | 151.00% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PepGen Inc | 0.00 | -80.33m | 449.90m | 64.00 | -- | 2.51 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Editas Medicine Inc | 69.41m | -166.13m | 453.13m | 265.00 | -- | 1.54 | -- | 6.53 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Esperion Therapeutics Inc | 229.74m | -86.51m | 456.60m | 240.00 | -- | -- | -- | 1.99 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Voyager Therapeutics Inc | 119.04m | -3.04m | 459.08m | 162.00 | -- | 1.34 | 302.43 | 3.86 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Nkarta Inc | 0.00 | -116.20m | 460.15m | 150.00 | -- | 0.9713 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 465.17m | 255.00 | -- | 0.7964 | -- | 28.98 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 470.48m | 127.00 | -- | 5.93 | -- | 94.10 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Korro Bio Inc | 0.00 | -81.19m | 471.07m | 94.00 | -- | 2.69 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Fulcrum Therapeutics Inc | 2.51m | -99.43m | 474.85m | 76.00 | -- | 2.22 | -- | 189.18 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Lenz Therapeutics Inc | 0.00 | -117.37m | 475.96m | 6.00 | -- | 2.40 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Ocugen Inc | 7.05m | -58.50m | 476.06m | 65.00 | -- | 15.73 | -- | 67.53 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 483.04m | 19.00 | -- | 4.90 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Applied Therapeutics Inc | -477.00k | -193.56m | 484.49m | 26.00 | -- | 7.20 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 489.81m | 118.00 | -- | 4.53 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
Tscan Therapeutics Inc | 14.81m | -96.80m | 490.57m | 161.00 | -- | 3.62 | -- | 33.12 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 727.21k | 9.07% |
Deep Track Capital LPas of 26 Apr 2024 | 714.29k | 8.90% |
Point72 Asset Management LPas of 31 Mar 2024 | 542.66k | 6.77% |
Eventide Asset Management LLCas of 31 Mar 2024 | 537.49k | 6.70% |
Citadel Advisors LLCas of 31 Mar 2024 | 529.17k | 6.60% |
Cormorant Asset Management LPas of 31 Mar 2024 | 529.17k | 6.60% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 419.23k | 5.23% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 264.94k | 3.30% |
Verition Fund Management LLCas of 31 Mar 2024 | 140.09k | 1.75% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 79.71k | 0.99% |